Evaluating bowel preparation tolerability in IBD: a phase 3 post-hoc comparison of mannitol and PEG-ASC.

Frontiers in gastroenterology (Lausanne, Switzerland) Pub Date : 2025-08-25 eCollection Date: 2025-01-01 DOI:10.3389/fgstr.2025.1630479

Gian Eugenio Tontini, Alessandro Rimondi, Flavio Caprioli, Giovanni Aldinio, Luca Pastorelli, Franco Radaelli, Cristiano Spada, Maurizio Vecchi

{"title":"Evaluating bowel preparation tolerability in IBD: a phase 3 post-hoc comparison of mannitol and PEG-ASC.","authors":"Gian Eugenio Tontini, Alessandro Rimondi, Flavio Caprioli, Giovanni Aldinio, Luca Pastorelli, Franco Radaelli, Cristiano Spada, Maurizio Vecchi","doi":"10.3389/fgstr.2025.1630479","DOIUrl":null,"url":null,"abstract":"Bowel preparation is a significant challenge for patients undergoing colonoscopy, especially in Inflammatory Bowel Disease (IBD) patients. Oral mannitol (OM), an ultra-low-volume, single-dose osmotic laxative with a sweet taste, could improve patient tolerability. We performed a post-hoc analysis of the phase 3, multicentre, randomized, endoscopist-blinded SATISFACTION trial to compare same-day OM versus standard split-dose 2L polyethylene glycol plus ascorbate (PEG-ASC) for bowel preparation in IBD patients. Fifty-five IBD patients (24 OM, 31 PEG-ASC) were assessed for bowel cleansing efficacy, endoscopic outcomes, safety, and patient satisfaction. OM demonstrated superior tolerability, including ease of use (88% vs. 71%), taste satisfaction (75% vs. 6%), and willingness to reuse (96% vs. 71%). OM also reduced intake duration (32 vs. 107 minutes) and time to evacuation (57 vs. 91 minutes), with comparable efficacy, cleansing quality, and safety. In conclusion, same-day OM preparation enhances satisfaction and adherence in IBD patients, offering a safe, effective alternative to standard protocols.","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"4 ","pages":"1630479"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12952433/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in gastroenterology (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fgstr.2025.1630479","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Bowel preparation is a significant challenge for patients undergoing colonoscopy, especially in Inflammatory Bowel Disease (IBD) patients. Oral mannitol (OM), an ultra-low-volume, single-dose osmotic laxative with a sweet taste, could improve patient tolerability. We performed a post-hoc analysis of the phase 3, multicentre, randomized, endoscopist-blinded SATISFACTION trial to compare same-day OM versus standard split-dose 2L polyethylene glycol plus ascorbate (PEG-ASC) for bowel preparation in IBD patients. Fifty-five IBD patients (24 OM, 31 PEG-ASC) were assessed for bowel cleansing efficacy, endoscopic outcomes, safety, and patient satisfaction. OM demonstrated superior tolerability, including ease of use (88% vs. 71%), taste satisfaction (75% vs. 6%), and willingness to reuse (96% vs. 71%). OM also reduced intake duration (32 vs. 107 minutes) and time to evacuation (57 vs. 91 minutes), with comparable efficacy, cleansing quality, and safety. In conclusion, same-day OM preparation enhances satisfaction and adherence in IBD patients, offering a safe, effective alternative to standard protocols.

查看原文本刊更多论文

评估肠准备对IBD的耐受性：甘露醇和PEG-ASC的3期事后比较

对于接受结肠镜检查的患者，特别是炎症性肠病（IBD）患者，肠道准备是一项重大挑战。口服甘露醇（OM）是一种超低体积、单剂量的渗透性泻药，具有甜味，可以提高患者的耐受性。我们对3期、多中心、随机、内窥镜师盲法的SATISFACTION试验进行了事后分析，比较同日OM与标准分剂量2L聚乙二醇加抗坏血酸（PEG-ASC）用于IBD患者肠道准备的效果。对55名IBD患者（24名OM， 31名PEG-ASC）进行了肠道清洁疗效、内镜结果、安全性和患者满意度的评估。OM表现出优越的耐受性，包括易用性（88%对71%），味道满意度（75%对6%）和重复使用的意愿（96%对71%）。OM还缩短了吸入时间（32分钟对107分钟）和疏散时间（57分钟对91分钟），具有相当的功效、清洁质量和安全性。总之，当天OM准备提高了IBD患者的满意度和依从性，为标准方案提供了一种安全、有效的替代方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in gastroenterology (Lausanne, Switzerland)

自引率

0.00%

发文量